Global Travelan sales for the second half of FY26 reached AUD 3.5 million, up 7% year on year. Fourth-quarter sales were AUD 2.0 million, representing a 2% increase. Australian FY26 sales were reported at AUD 5.8 million, making the domestic market an important contributor …
Earlier in 2026, Epsilon Pharma entered a manufacturing agreement with Puro NZ. The agreement added another commercial relationship to Epsilon’s manufacturing operations and followed the company’s efforts to build utilisation of its pharmaceutical production capabilities. Epsilon also received Halal Australia certification in February, broadening …
CEO and Managing Director Vikesh Ramsunder said FY26 demonstrated that Sigma is not simply larger after the merger, but structurally stronger, with a network approaching 1,000 pharmacies globally. He noted that Normalised proforma EBIT for FY24, at the time of the merger as disclosed …
Under the terms of the agreement, H&S Global will operate as Biome's sales and operational partner on the ground in China, purchasing product from Biome for resale in the territory and establishing and operating Biome'sBrandstores and channel presence. Biome will retain control and ownership …
Since 1 June 2016, only products for which the PDAC Contractor has issued written coding verification and which appear on the Product Classification List may be billed to Medicare under HCPCS code E2510. Without that verification, claims submitted under the code are denied as …
In Australia,Revenueincreased 7.8% and underlying EBIT grew 11.2%, driven by higher activity growth, increased acuity and theatre utilisation, improved privateHealth Insurancerevenue indexation and cost management. The result was partially offset by a reduced contribution from the Joondalup Health Campus, reflecting a new funding mechanism …
The catalyst was the FY26 result. Biome Australia’s FY26 result reflected a company scaling its probiotic and supplement brands, with record revenue underscoring demand.
PolyNovo has developed a biodegradable polymer technology, marketed under its NovoSorb brand, used in the treatment of severe wounds, burns, and in reconstructive and hernia repair surgery. The technology functions as a scaffold that supports the body's own tissue regeneration process before gradually being …
Rhythm Biosciences has been developing a blood-based diagnostic test designed to support the detection of colorectal cancer, positioning it as a potential complement or alternative to existing screening methods such as faecal-based tests or colonoscopy. A blood-based approach, if successfully developed and approved, could …
Vitura Health is one of Australia's more established players in the medicinal cannabis space, operating across the value chain from cultivation andManufacturingthrough to distribution and patient access. The company has built a diversified model that includes its own branded cannabis products, a wholesale distributionBusinesssupplying …